PT  - JOURNAL ARTICLE
AU  - Antoine Danchin
AU  - Oriane Pagani-Azizi
AU  - Gabriel Turinici
AU  - Ghozlane Yahiaoui
TI  - COVID-19 adaptive humoral immunity models: non-neutralizing versus antibody-disease enhancement scenarios
AID  - 10.1101/2020.10.21.20216713
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.21.20216713
4099  - http://medrxiv.org/content/early/2020/10/23/2020.10.21.20216713.short
4100  - http://medrxiv.org/content/early/2020/10/23/2020.10.21.20216713.full
AB  - The interplay between the virus, infected cells and the immune responses to SARS-CoV-2 is still under debate. Extending the basic model of viral dynamics we propose here a formal approach to describe the neutralizing versus non-neutralizing scenarios and compare with the possible effects of antibody-dependent enhancement (ADE). The theoretical model is consistent with data available from the literature and conclusions show that, while both non-neutralizing scenarios and ADE give rise to similar final virus clearance, the non-neutralizing antibodies can induce permanent high levels of antibody production with documented unfavorable impact on the disease progression and outcome. We also discuss the implications on secondary infections.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGhozlane Yahiaoui is supported by the Engineering and Physical Sciences Research Council (EPSRC) U.K.: CDT Grant Ref. EP/L015811/1. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No direct human data used.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available from public sources.